



# Director Dealings

March 19, 2019 9:05 PM EDT

Released : March 19, 2019 17:05

RNS Number : 3554T

MaxCyte, Inc.

19 March 2019

## **MaxCyte, Inc.**

("MaxCyte" or the "Company")

### **Director Dealings Issue of Equity**

**Gaithersburg, Maryland - 19 March 2019:** MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that J. Stark Thompson, Non-Executive Chairman of the Company, has exercised options over 25,000 shares of common stock of 0.1 pence of the Company ("Common Stock") ("Exercise"). In order to fund a near term personal tax liability, the 25,000 new shares of Common Stock issued pursuant to the Exercise ("New Common Stock") have today been sold by Dr Thompson at a price of 180 pence per Common Stock ("Sale"). Dr Thompson has no current intention of making further sales of MaxCyte shares.

Following the Exercise and Sale, Dr Thompson's holding of Common Stock remains unchanged at a total of 110,918 Common Stock representing a total of 0.2% of the issued share capital of the Company. Dr Thompson holds a further 239,533 options over Common Stock.

#### **Total voting rights**

The New Common Stock will be allocated out of the common stock the subject of the block listing announced on 2 May 2017. The New Common Stock will rank pari

passu with the existing shares of common stock of the Company. The total issued stock capital of the Company following the above will be 57,316,500 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 51,357,764 and the number of restricted shares of Common Stock trading under the symbol 'MXCS' is 5,958,736.

**This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").**

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name	J. Stark Thompson
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Non-Executive Chairman and PDMR
b)	Initial notification/Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	Exercise of options and Sale of Common Stock
b)	Identification Code	US57777K1060

c)	Nature of the transaction	Exercise of options and Sale of Common Stock by PDMR	
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		N/A	25,000 (option exercise)
		180.00 pence	25,000 (sale of common stock)
e)	Aggregated information	N/A	
	- Aggregated volume	25,000	
	- Price	180.00 (sale of common stock)	
f)	Date of the transaction	19 March 2019	
g)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	

### About MaxCyte

MaxCyte is a clinical-stage global cell-based medicines and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA™ therapies for its own pipeline, with its first drug candidate in a Phase 1 clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its core business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 70 partnered program licenses in cell therapy including more than 35 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit [www.maxcyte.com](http://www.maxcyte.com).

For further information, please contact:

**MaxCyte Inc.**

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

***Nominated Adviser and Broker***

**Panmure Gordon**

+44 (0)20 7886 2500

Emma Earl

Freddy Crossley

**Corporate Broking**

James Stearns

***Financial PR Adviser***

**Consilium Strategic Communications**

+44 (0)203 709 5700

Mary-Jane Elliott

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

Chris Welsh

Sukaina Virji

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

END

DSHJLMFTMBABBLL